



COVID-19 Vaccination: Considerations for Public Health and Policy

Guest Editors:

Dr. Jovana Stojanovic

stojanovic.jovana1988@gmail.com

Prof. Dr. Kim L. Lavoie

lavoie.kim@uqam.ca

Prof. Dr. Simon Bacon

Simon.Bacon@concordia.ca

Deadline for manuscript
submissions:

31 August 2022

Message from the Guest Editors

Dear Colleagues,

Development and large-scale implementation of COVID-19 vaccination represent a promising tool for reaching herd immunity and ending this global crisis.

In this Special Issue, original research articles and different types of evidence-summaries are welcome. Research areas may include (but not limited to) the following:

1. COVID-19 vaccine acceptance, hesitancy, and refusal, including assessments of the evolving epidemiology and understating of individual, group-level and context-specific determinants of these phenomena.
2. Monitoring and continued development of COVID-19 vaccines, including efficacy and effectiveness of vaccines in the context of emerging variants, safety, booster doses, mixing and matching vaccines.
3. Public health and policy issues, including vaccine deployment, ensuring equitable access, communication strategies for encouraging vaccine uptake and introduction of vaccine passports.

We look forward to receiving your contributions. Drs. Stojanovic and Lavoie

Dr. Jovana Stojanovic

Prof. Dr. Kim L. Lavoie

Prof. Dr. Simon Bacon

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access:— free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPlus / SciFinder](#), and many [other databases](#).

Journal Rank: [JCR - Q2 \(Immunology\)](#)

Contact Us

Vaccines
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com